ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, Abe Y, Ohkawa K, Mita E, Hayashi Y, Hikita H, Sakamori R, Tatsumi T, Taguchi A, Eguchi H, Takehara T.
Myojin Y, et al. Among authors: tanaka s.
Clin Cancer Res. 2021 Feb 15;27(4):1150-1161. doi: 10.1158/1078-0432.CCR-20-3382. Epub 2020 Dec 7.
Clin Cancer Res. 2021.
PMID: 33288659